| | | Page | | |||
| | | | 1 | | | |
| | | | 3 | | | |
| | | | 3 | | | |
| | | | 7 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | ||||
| | ||||||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | |
Proposal | | | Vote Required | | | Discretionary Voting Permitted? | |
Election of Directors | | | Plurality | | | No | |
Approval of the Ratification of the Appointment of Ernst & Young LLP as our Independent Registered Public Accounting Firm | | | Majority of votes cast | | | Yes | |
Name | | | Positions and Offices Held with Scholar Rock | | | Director Since | | | Age | |
Nagesh Mahanthappa | | | Director | | | 2021 | | | 57 | |
Joshua Reed | | | Director | | | 2021 | | | 49 | |
Name | | | Positions and Offices Held with Scholar Rock | | | Director Since | | | Age | |
David Hallal | | | Director | | | 2017 | | | 56 | |
Kristina Burow | | | Director | | | 2014 | | | 49 | |
Michael Gilman, Ph.D. | | | Director | | | 2013 | | | 68 | |
Name | | Positions and Offices Held with Scholar Rock | | Director Since | | Class and Year in Which Term Will Expire | | Age | | | Positions and Offices Held with Scholar Rock | | Director Since | | Class and Year in Which Term Will Expire | | Age | | ||||||||
David Hallal | | Director | | 2017 | | Class II — 2023 | | 55 | | |||||||||||||||||
Kristina Burow | | Director | | 2014 | | Class II — 2023 | | 48 | | |||||||||||||||||
Michael Gilman, Ph.D. | | Director | | 2013 | | Class II — 2023 | | 67 | | |||||||||||||||||
Srinivas Akkaraju, M.D., Ph.D. | | Director | | 2022 | | Class I — 2025 | | 55 | | |||||||||||||||||
Jay Backstrom, M.D., M.P.H. | | Director | | 2022 | | Class I — 2025 | | 68 | | |||||||||||||||||
Joshua Reed | | Director | | 2021 | | Class I — 2025 | | 50 | | |||||||||||||||||
Richard H. Brudnick | | Director | | 2023 | | Class III — 2024 | | 66 | | |||||||||||||||||
Jeffrey S. Flier, M.D. | | Director | | 2016 | | Class III — 2024 | | 74 | | | Director | | 2016 | | Class III — 2024 | | 75 | | ||||||||
Amir Nashat, Sc. D. | | Director | | 2012 | | Class III — 2024 | | 49 | | | Director | | 2012 | | Class III — 2024 | | 50 | | ||||||||
Akshay Vaishnaw, M.D., Ph.D. | | Director | | 2019 | | Class III — 2024 | | 59 | | | Director | | 2019 | | Class III — 2024 | | 60 | |
| Board Size: | | | | | | | | | | | | | | | | | | | |
| Total Number of Directors | | | | | 8 | | | | | | | | | | | | | | |
| Gender: | | | Male | | | Female | | | Non-Binary | | | Gender Undisclosed | | ||||||
| Number of directors based on gender identity | | | | | 7 | | | | | | 1 | | | | | | | | |
| Number of directors who identify in any of the categories below: | | | | | | | | | | | | | | | | | | | |
| African American or Black | | | | | 1 | | | | | | | | | | | | | | |
| Alaskan Native or American Indian | | | | | | | | | | | | | | | | | | | |
| Asian | | | | | 3 | | | | | | | | | | | | | | |
| Hispanic or Latinx | | | | | | | | | | | | | | | | | | | |
| Native Hawaiian or Pacific Islander | | | | | | | | | | | | | | | | | | | |
| White | | | | | 3 | | | | | | 1 | | | | | | | | |
| Two or More Races or Ethnicities | | | | | | | | | | | | | | | | | | | |
| LGBTQ+ | | | | | | | | | | | | | | | | | | | |
| Undisclosed | | | | | | | | | | | | | | | | | | | |
| Board Size: | | | | | | ||||||||||||||
| Total Number of Directors | | | | | 10 | | | | | | | | | | | | | | |
| Gender: | | | Male | | | Female | | | Non-Binary | | | Did not Disclose Gender | | ||||||
| Number of directors based on gender identity | | | | | 9 | | | | | | 1 | | | | | | | | |
| Number of directors who identify in any of the categories below: | | | | | | | | | | | | | | | | | | | |
| African American or Black | | | | | 1 | | | | | | | | | | | | | | |
| Alaskan Native or American Indian | | | | | | | | | | | | | | | | | | | |
| Asian | | | | | 3 | | | | | | | | | | | | | | |
| Hispanic or Latinx | | | | | | | | | | | | | | | | | | | |
| Native Hawaiian or Pacific Islander | | | | | | | | | | | | | | | | | | | |
| White | | | | | 5 | | | | | | 1 | | | | | | | | |
| Two or More Races or Ethnicities | | | | | | | | | | | | | | | | | | | |
| LGBTQ+ | | | | | | | | | | | | | | | | | | | |
| Undisclosed | | | | | | | | | | | | | | | | | | | |
Name | | Position Held with Scholar Rock | | Officer Since | | Age | | | Position Held with Scholar Rock | | Officer Since | | Age | | ||||||
Nagesh K. Mahanthappa, Ph.D. | | Interim Chief Executive Officer & President | | 2021 | | 58 | | |||||||||||||
Gregory J. Carven, Ph.D. | | Chief Scientific Officer | | 2021 | | 46 | | |||||||||||||
Yung H. Chyung, M.D. | | Chief Medical Officer | | 2016 | | 46 | | |||||||||||||
Jay Backstrom, M.D., M.P.H. | | Chief Executive Officer & President | | 2022 | | 68 | | |||||||||||||
Junlin Ho, J.D. | | General Counsel & Corporate Secretary | | 2021 | | 43 | | | General Counsel & Corporate Secretary | | 2021 | | 44 | | ||||||
Jing Marantz, M.D., Ph.D., M.B.A. | | Chief Medical Officer | | 2022 | | 58 | | |||||||||||||
Edward H. Myles, M.B.A. | | Chief Operating Officer and Chief Financial Officer | | 2020 | | 50 | | | Chief Operating Officer and Chief Financial Officer | | 2020 | | 51 | | ||||||
Caryn Parlavecchio | | Chief Human Resources Officer | | 2021 | | 50 | | | Chief Human Resources Officer | | 2021 | | 51 | | ||||||
Mo Qatanani, Ph.D. | | Senior Vice President and Head of Research | | 2022 | | 49 | | |||||||||||||
Tracey Sacco | | Chief Commercial Officer | | 2022 | | 46 | |
| | 2021 | | 2020 | | | 2022 | | 2021 | | ||||||||||||||||
Audit fees(1) | | | $ | 825 | | | | $ | 619 | | | | | $ | 873 | | | | $ | 825 | | | ||||
Audit-related fees(2) | | | | — | | | | | 40 | | | | | | — | | | | | — | | | ||||
Tax fees(3) | | | | 169 | | | | | 179 | | | | | | 63 | | | | | 169 | | | ||||
All other fees(4) | | | | 1 | | | | | 1 | | | | | | — | | | | | 1 | | | ||||
Total fees | | | $ | 995 | | | | $ | 839 | | | | | $ | 936 | | | | $ | 995 | | |
Name | | Fees Earned or Paid in Cash ($)(1) | | Stock Awards ($) | | Option Awards ($)(3) | | Total ($) | | | Fees Earned or Paid in Cash ($)(1) | | Stock Awards ($) | | Option Awards ($)(4) | | Total ($) | | ||||||||||||||||||||||||||||||||
David Hallal | | | | 166,972 | | | | | — | | | | | 148,363(4) | | | | | 315,335 | | | | | | 169,804 | | | | | — | | | | | 146,125(5) | | | | | 315,929 | | | ||||||||
Srinivas Akkaraju, M.D., Ph.D. | | | | 17,282(2) | | | | | — | | | | | 376,729(6) | | | | | 394,011 | | | |||||||||||||||||||||||||||||
Kristina Burow | | | | 56,472 | | | | | — | | | | | 148,363(5) | | | | | 204,835 | | | | | | 60,195 | | | | | — | | | | | 96,670(7) | | | | | 156,865 | | | ||||||||
Jeffrey S. Flier, M.D. | | | | 57,972 | | | | | — | | | | | 148,363(6) | | | | | 206,335 | | | | | | 59,603 | | | | | — | | | | | 96,670(8) | | | | | 156,273 | | | ||||||||
Michael Gilman, Ph.D. | | | | 53,583 | | | | | — | | | | | 148,363(7) | | | | | 201,946 | | | | | | 53,099 | | | | | — | | | | | 146,125(9) | | | | | 199,224 | | | ||||||||
Amir Nashat, Sc.D. | | | | 46,472(2) | | | | | — | | | | | 148,363(8) | | | | | 194,835 | | | | | | 48,997(3) | | | | | — | | | | | 96,670(10) | | | | | 145,667 | | | ||||||||
Joshua Reed | | | | 43,389 | | | | | — | | | | | 746,318(9) | | | | | 789,707 | | | | | | 57,995 | | | | | — | | | | | 96,670(11) | | | | | 154,665 | | | ||||||||
Akshay Vaishnaw, M.D., Ph.D. | | | | 51,528 | | | | | — | | | | | 148,363(10) | | | | | 199,891 | | | | | | 52,103 | | | | | — | | | | | 146,125(12) | | | | | 198,228 | | |
| | 2021 Annual Retainer | | | 2022 Annual Retainer | | ||||||||
Board of Directors: | | | | | | | | | | | | | ||
Nonemployee member | | | $ | 40,000(1) | | | | | $ | 40,000 | | | ||
Additional fee for Non-Executive Chairman of the Board | | | $ | 115,000 | | | | | $ | 115,000 | | | ||
Audit Committee: | | | | | | | | | | | | | ||
Member | | | $ | 7,500 | | | | | $ | 10,000(1) | | | ||
Additional fee for Chairman | | | $ | 7,500 | | | | | $ | 10,000(1) | | | ||
Compensation Committee: | | | | | | | | | | | | | ||
Member | | | $ | 5,000 | | | | | $ | 6,000(2) | | | ||
Additional fee for Chairman | | | $ | 5,000 | | | | | $ | 6,000(2) | | | ||
Nominating and Corporate Governance Committee: | | | | | | | | | | | | | ||
Member | | | $ | 4,000 | | | | | $ | 5,000(3) | | | ||
Additional fee for Chairman | | | $ | 4,000 | | | | | $ | 5,000(3) | | | ||
Science, Innovation and Technology Committee: | | | | | | | | | | | | | ||
Member | | | $ | 7,500 | | | | | $ | 7,500 | | | ||
Additional fee for Chairman | | | $ | 7,500 | | | | | $ | 7,500 | | |
Name and Principal Position | | Year | | Salary ($) | | Stock Awards ($)(1) | | Option Award ($)(1) | | Non-Equity Incentive Plan Compensation ($)(2) | | All Other Compensation ($)(3) | | Total ($) | | | Year | | Salary ($) | | Stock Awards ($)(1) | | Option Award ($)(1) | | Non-Equity Incentive Plan Compensation ($)(2) | | All Other Compensation ($)(3) | | Total ($) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nagesh K. Mahanthappa, Ph.D. Interim Chief Executive Officer and President | | | | | 2021 | | | | | 219,420(4) | | | | | — | | | | | 4,739,043(5) | | | | | 128,765 | | | | | 8,036(15) | | | | | 5,095,264 | | | |||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2020 | | | | | 306,904(6) | | | | | 40,743(7) | | | | | 2,936,796(8) | | | | | — | | | | | 846,648(9) | | | | | 4,131,091 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
Edward H. Myles Chief Operating Officer & Chief Financial Officer | | | | | 2021 | | | | | 444,769 | | | | | 1,423,160 | | | | | 3,477,028 | | | | | 158,331 | | | | | 12,765(16) | | | | | 5,516,053 | | | |||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2020 | | | | | 193,500(10) | | | | | — | | | | | 2,683,211(11) | | | | | 208,980 | | | | | 30,664(18) | | | | | 3,116,355 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
Yung H. Chyung M.D., Chief Medical Officer | | | | 2021 | | | | | 444,758 | | | | | 928,148 | | | | | 2,267,627 | | | | | 158,331 | | | | | 10,518(16) | | | | | 3,809,382 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||
Stuart A. Kingsley Former President and Chief Executive Officer | | | | | 2021 | | | | | 318,500(12) | | | | | 2,475,060 | | | | | 6,047,006 | | | | | — | | | | | 775,401(13) | | | | | 9,615,967 | | | |||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2020 | | | | | 238,000(17) | | | | | — | | | | | 4,396,154(14) | | | | | 312,000 | | | | | 6,692 | | | | | 4,952,846 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
Jay Backstrom, M.D., M.P.H. President and Chief Executive Officer | | | | 2022 | | | | | 159,231(4) | | | | | — | | | | | 6,809,500 | | | | | 100,603 | | | | | 6,925(5) | | | | | 7,076,259 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||
Edward H. Myles, M.B.A. Chief Operating Officer & Chief Financial Officer | | | | | 2022 | | | | | 466,577 | | | | | 1,402,885 | | | | | 1,038,517 | | | | | 188,201 | | | | | 13,707(6) | | | | | 3,109,887 | | | |||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2021 | | | | | 444,769 | | | | | 1,423,160 | | | | | 3,477,028 | | | | | 158,331 | | | | | 12,765 | | | | | 5,516,053 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
Junlin Ho, J.D. General Counsel and Secretary | | | | 2022 | | | | | 394,039 | | | | | 899,130 | | | | | 665,497 | | | | | 159,185 | | | | | 10,505(6) | | | | | 2,128,356 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||
Greg Carven, Ph.D. Former Chief Scientific Officer | | | | 2022 | | | | | 333,862(7) | | | | | 1,329,010(8) | | | | | 1,383,490(9) | | | | | — | | | | | 40,609(10) | | | | | 3,086,971 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||
Nagesh K. Mahanthappa, Ph.D. Former Interim Chief Executive Officer and President | | | | | 2022 | | | | | 480,600(11) | | | | | 1,429,236(12) | | | | | 862,414(13) | | | | | — | | | | | 71,611(14) | | | | | 2,843,861 | | | |||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2021 | | | | | 219,420(15) | | | | | — | | | | | 4,739,043(16) | | | | | 128,765 | | | | | 8,036 | | | | | 5,095,264 | | |
| | | | | | | Option Awards | | Stock Awards | | | | | | | | Option Awards | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Name and Principal Position(9) | | Grant Date | | Number of Securities Underlying Unexercised Options (# Exercisable) | | Number of Securities Underlying Unexercised Options (# Unexercisable) | | Option Exercise Price | | Expiration Date | | Number of Shares or Units of Stock That Have Not Vested (#) | | Market Value of Shares or Units of Stock that Have Not Vested ($)(1) | | | Grant Date | | Number of Securities Underlying Unexercised Options (# Exercisable) | | Number of Securities Underlying Unexercised Options (# Unexercisable) | | Option Exercise Price | | Expiration Date | | Number of Shares or Units of Stock That Have Not Vested (#) | | Market Value of Shares or Units of Stock that Have Not Vested ($)(1) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Jay Backstrom, M.D., M.P.H. President and Chief Executive Officer | | | | 09/20/2022(2) | | | | | — | | | | | 1,000,000 | | | | $ | 8.85 | | | | | 09/20/2032 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||
Edward H. Myles, M.B.A. Chief Operating Officer and Chief Financial Officer | | | | | 07/16/2020(3) | | | | | 78,125 | | | | | 109,375 | | | | $ | 13.83 | | | | | 07/16/2030 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/01/2021(4) | | | | | 35,218 | | | | | 45,282 | | | | $ | 58.93 | | | | | 02/01/2031 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/01/2021(5) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 18,113 | | | | $ | 163,923 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/14/2022(6) | | | | | 10,781 | | | | | 46,719 | | | | $ | 18.08 | | | | | 02/14/2032 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/14/2022(7) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 57,500 | | | | $ | 520,375 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 06/16/2022(8) | | | | | 12,458 | | | | | 62,292 | | | | $ | 4.86 | | | | | 06/16/2032 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 06/16/2022(9) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 74,750 | | | | $ | 676,488 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
Junlin Ho, J.D. General Counsel and Secretary | | | | | 04/03/2018(18) | | | | | 42,974 | | | | | — | | | | $ | 7.17 | | | | | 04/03/2028 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||
| | | 05/23/2018(11) | | | | | 7,005 | | | | | — | | | | $ | 14.00 | | | | | 05/23/2028 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/31/2019(12) | | | | | 10,125 | | | | | — | | | | $ | 15.11 | | | | | 01/31/2029 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/06/2020(13) | | | | | 25,128 | | | | | 11,422 | | | | $ | 13.52 | | | | | 02/06/2030 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 03/23/2020(19) | | | | | 6,462 | | | | | 2,938 | | | | $ | 14.75 | | | | | 03/23/2030 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/01/2021(4) | | | | | 16,843 | | | | | 21,657 | | | | $ | 58.93 | | | | | 02/01/2031 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/01/2021(5) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 8,663 | | | | $ | 78,400 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/14/2022(6) | | | | | 7,031 | | | | | 30,469 | | | | $ | 18.08 | | | | | 02/14/2032 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/14/2022(7) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 37,500 | | | | $ | 339,375 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 06/16/2022(8) | | | | | 7,583 | | | | | 37,917 | | | | $ | 4.86 | | | | | 06/16/2032 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 06/16/2022(9) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 45,500 | | | | $ | 411,775 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
Greg Carven, Ph.D. Former Chief Scientific Officer | | | | | 02/20/2018(10) | | | | | 20,283 | | | | | — | | | | $ | 5.77 | | | | | 02/20/2028 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||
| | | 05/23/2018(11) | | | | | 4,399 | | | | | — | | | | $ | 14.00 | | | | | 05/23/2028 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/31/2019(12) | | | | | 22,136 | | | | | — | | | | $ | 15.11 | | | | | 01/31/2029 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/06/2020(13) | | | | | 26,683 | | | | | 12,130 | | | | $ | 13.52 | | | | | 02/06/2030 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 05/29/2020(20) | | | | | 31,250 | | | | | 18,750 | | | | $ | 18.40 | | | | | 05/29/2030 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/01/2021(4) | | | | | 18,375 | | | | | 23,625 | | | | $ | 58.93 | | | | | 02/01/2031 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/01/2021(5) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 9,450 | | | | $ | 85,523 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/14/2022(6) | | | | | 6,562 | | | | | 28,438 | | | | $ | 18.08 | | | | | 02/14/2032 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/14/2022(7) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 35,000 | | | | $ | 316,750 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 06/16/2022(8) | | | | | 7,583 | | | | | 37,917 | | | | $ | 4.86 | | | | | 06/16/2032 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 06/16/2022(9) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 45,500 | | | | $ | 411,775 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
Nagesh K. Mahanthappa, Ph.D. Interim Chief Executive Officer and President | | | | | 02/20/2018(2) | | | | | 39,407 | | | | | 13,136 | | | | $ | 5.77 | | | | | 02/20/2028 | | | | | — | | | | | — | | | | | | | 02/20/2018(10) | | | | | 52,543 | | | | | — | | | | $ | 5.77 | | | | | 02/20/2028 | | | | | — | | | | | — | | | ||||||||||||
| | | 05/23/2018(3) | | | | | 27,618 | | | | | 18,412 | | | | $ | 14.00 | | | | | 05/23/2028 | | | | | — | | | | | — | | | | | | 05/23/2018(11) | | | | | 46,030 | | | | | — | | | | $ | 14.00 | | | | | 05/23/2028 | | | | | — | | | | | — | | | |||||||||||||||
| | | 01/31/2019(4) | | | | | 24,742 | | | | | 32,500 | | | | $ | 15.11 | | | | | 01/31/2029 | | | | | — | | | | | — | | | | | | 01/31/2019(12) | | | | | 57,242 | | | | | — | | | | $ | 15.11 | | | | | 01/31/2029 | | | | | — | | | | | — | | | |||||||||||||||
| | | 02/06/2020(5) | | | | | 30,750 | | | | | 92,250 | | | | $ | 13.52 | | | | | 02/06/2030 | | | | | — | | | | | — | | | | | | 02/06/2020(13) | | | | | 71,750 | | | | | 51,250 | | | | $ | 13.52 | | | | | 02/06/2030 | | | | | — | | | | | — | | | |||||||||||||||
Edward H. Myles Chief Operating Officer and Chief Financial Officer | | | | | 07/16/2020(6) | | | | | 15,625 | | | | | 171,875 | | | | $ | 13.83 | | | | | 07/16/2030 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/01/2021(7) | | | | | 15,093 | | | | | 65,407 | | | | $ | 58.93 | | | | | 02/01/2031 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/01/2021(8) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 24,150 | | | | $ | 599,886 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
Yung H. Chyung, M.D., Chief Medical Officer | | | | | 02/20/2018(2) | | | | | 39,406 | | | | | 2,628 | | | | $ | 5.77 | | | | | 02/20/2028 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/31/2019(4) | | | | | 42,000 | | | | | 14,000 | | | | $ | 15.11 | | | | | 01/31/2029 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/06/2020(5) | | | | | 32,812 | | | | | 42,188 | | | | $ | 13.52 | | | | | 02/06/2030 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/21/2021(7) | | | | | 9,843 | | | | | 42,657 | | | | $ | 58.93 | | | | | 02/01/2031 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/21/2021(8) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 15,750 | | | | $ | 391,230 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
Nagesh K. Mahanthappa, Ph.D. Interim Chief Executive Officer and President | | | | | 02/14/2022(14) | | | | | 37,500 | | | | | 12,500 | | | | $ | 18.08 | | | | | 02/14/2032 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/14/2022(15) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 50,000 | | | | $ | 452,500 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 06/16/2022(16) | | | | | 25,000 | | | | | 25,000 | | | | $ | 4.86 | | | | | 06/16/2032 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 06/16/2022(17) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 50,000 | | | | $ | 452,500 | | |
Plan Category | | Number of securities to be issued upon exercise of outstanding options, warrants and rights (a) | | Weighted-average exercise price of outstanding options, warrants and rights (b) | | Number of securities available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (c) | | | Number of securities to be issued upon exercise of outstanding options, warrants and rights (a) | | Weighted-average exercise price of outstanding options, warrants and rights (b) | | Number of securities available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (c) | | ||||||||||||||||||||||||
Equity compensation plans approved by security holders (1) | | | | 4,058,301 | | | | $ | 25.55(2) | | | | | 3,531,464(3) | | | | | | 6,660,306 | | | | $ | 19.20(2) | | | | | 2,552,962(3) | | | ||||||
Equity compensation plans not approved by security holders | | | | — | | | | | — | | | | | — | | | | | | 1,250,000 | | | | | 8.80 | | | | | 750,000 | | | ||||||
Total | | | | 4,058,301 | | | | $ | 25.55 | | | | | 3,531,464 | | | | | | 7,910,306 | | | | | | | | | | 3,302,962 | | |
Name | | | Shares of Common Stock | | | Shares of Common Stock Issuable Upon Exercise of Pre-Funded Warrants | | | Warrants | | | Total Purchase Price Paid | | ||||||||||||
Entities Affiliated with Redmile Group, LLC(1) | | | | | — | | | | | | 15,306,123 | | | | | | 3,826,530 | | | | | $ | 74,998,472.09 | | |
Invus Public Equities, L.P.(3) | | | | | 6,300,034 | | | | | | — | | | | | | 1,575,008 | | | | | $ | 30,870,166.60 | | |
Entities Affiliated with Polaris Venture Partners(4) | | | | | 1,197,992 | | | | | | — | | | | | | 299,498 | | | | | $ | 5,870,160.80 | | |
Samsara BioCapital, L.P.(5) | | | | | 4,259,217 | | | | | | — | | | | | | 1,064,804 | | | | | $ | 20,870,163.30 | | |
Entities Affiliated with T. Rowe Price Associates, Inc.(6) | | | | | 2,549,512 | | | | | | — | | | | | | 637,378 | | | | | $ | 12,492,608.80 | | |
Entities Affiliated with FMR LLC(7) | | | | | 2,019,775 | | | | | | — | | | | | | 504,943 | | | | | $ | 9,896,897.50 | | |
Total | | | | | 16,326,530 | | | | | | 15,306,123 | | | | | | 7,908,161 | | | | | $ | 154,998,469.09 | | |
| | | Shares beneficially owned | | |||||||||
Name and address of beneficial owner(1) | | | Number | | | Percentage(1) | | ||||||
5% Stockholders: | | | | | | | | | | | | | |
ARCH Venture Fund VIII, L.P.(2) | | | | | 2,637,617 | | | | | | 7.5% | | |
Invus Public Equities, L.P.(3) | | | | | 2,450,000 | | | | | | 6.9% | | |
Entities affiliated with Polaris Venture Partners(4) | | | | | 2,549,435 | | | | | | 7.2% | | |
FMR LLC(5) | | | | | 5,266,219 | | | | | | 14.9% | | |
Redmile Group, LLC(6) | | | | | 3,624,880 | | | | | | 9.9% | | |
BB Biotech AG(7) | | | | | 2,275,125 | | | | | | 6.4% | | |
T. Rowe Price Associates, Inc.(8) | | | | | 5,262,601 | | | | | | 14.9% | | |
BlackRock, Inc.(9) | | | | | 2,288,026 | | | | | | 6.5% | | |
Named Executive Officers and Directors: | | | | | | | | | | | | | |
Stuart A. Kingsley(10) | | | | | — | | | | | | — | | |
Yung H. Chyung, M.D.,(11) | | | | | 357,653 | | | | | | 1.0% | | |
Edward H. Myles(12) | | | | | 79,483 | | | | | | * | | |
Nagesh K. Mahanthappa, Ph.D.(13) | | | | | 575,681 | | | | | | 1.6% | | |
David Hallal(14) | | | | | 459,793 | | | | | | 1.3% | | |
Kristina Burow(15) | | | | | 2,688,891 | | | | | | 7.6% | | |
Jeffrey S. Flier, M.D.(16) | | | | | 65,102 | | | | | | * | | |
Michael Gilman, Ph.D.(17) | | | | | 90,047 | | | | | | * | | |
Amir Nashat, Sc.D.(18) | | | | | 2,608,150 | | | | | | 7.4% | | |
Joshua Reed(19) | | | | | 6,066 | | | | | | * | | |
Akshay Vaishnaw, M.D., Ph.D.(20) | | | | | 51,884 | | | | | | * | | |
All executive officers and directors as a group (14 persons) | | | | | 7,251,190 | | | | | | 20.5% | | |
| | | Shares beneficially owned | | |||||||||
Name and address of beneficial owner(1) | | | Number | | | Percentage(1) | | ||||||
5% Stockholders: | | | | | | | | | | | | | |
ARCH Venture Fund VIII, L.P.(2) | | | | | 2,637,617 | | | | | | 5.1% | | |
Invus Public Equities, L.P.(3) | | | | | 10,555,278 | | | | | | 19.7% | | |
Entities affiliated with Polaris Venture Partners(4) | | | | | 4,046,925 | | | | | | 7.7% | | |
FMR LLC(5) | | | | | 7,825,250 | | | | | | 14.9% | | |
Redmile Group, LLC(6) | | | | | 5,146,946 | | | | | | 9.4% | | |
T. Rowe Price Associates, Inc.(7) | | | | | 7,672,398 | | | | | | 14.6% | | |
Samsara BioCapital, L.P.(8) | | | | | 5,663,632 | | | | | | 10.7% | | |
Named Executive Officers and Directors: | | | | | | | | | | | | | |
Jay Backstrom(9) | | | | | 12,500 | | | | | | * | | |
Edward H. Myles(10) | | | | | 213,852 | | | | | | * | | |
Junlin Ho(11) | | | | | 182,754 | | | | | | * | | |
Greg Carven, Ph.D.(12) | | | | | 204,414 | | | | | | * | | |
Nagesh K. Mahanthappa, Ph.D.(13) | | | | | 812,151 | | | | | | 1.6% | | |
David Hallal(14) | | | | | 459,793 | | | | | | * | | |
Srinivas Akkaraju(15) | | | | | 5,677,632 | | | | | | 10.9% | | |
Richard Brudnick(16) | | | | | 1,555 | | | | | | * | | |
Kristina Burow(17) | | | | | 2,688,891 | | | | | | 5.2% | | |
Jeffrey S. Flier, M.D.(18) | | | | | 65,102 | | | | | | * | | |
Michael Gilman, Ph.D.(19) | | | | | 90,047 | | | | | | * | | |
Amir Nashat, Sc.D.(20) | | | | | 4,105,640 | | | | | | 7.9% | | |
Joshua Reed(21) | | | | | 11,266 | | | | | | * | | |
Akshay Vaishnaw, M.D., Ph.D.(22) | | | | | 51,884 | | | | | | * | | |
All executive officers and directors as a group (14 persons)(23) | | | | | 13,613,592 | | | | | | 26.2% | | |